维生素D补充与成人骨折:对照试验Meta分析的系统性伞状综述
该伞状综述评估了维生素D(±钙)预防骨折的系统综述/Meta分析(SR/MA)的质量与结果差异原因。共纳入13篇钙/维生素D和19篇单用维生素D的SR/MA。钙/维生素D可降低髋部骨折(8/12篇,RR 0.61-0.84)和任何骨折(7/11篇,RR 0.74-0.95)风险,但单用维生素D或仅社区居住人群未见骨折风险降低。
要点
- 钙/维生素D降低髋部骨折风险(RR 0.61-0.84)和任何骨折风险(RR 0.74-0.95)。
- 单用维生素D对比安慰剂/对照未显示骨折风险降低。
- 仅评估社区居住人群的SR/MA未显示骨折风险降低。
核心结论
- 钙/维生素D可降低髋部骨折和任何骨折风险,可能由机构化人群的发现驱动。
- 单用维生素D或仅社区居住人群未见骨折风险降低。
研究设计与样本
- 伞状综述,检索4个数据库(2010-2020)、Epistemonikos及纳入SR/MA的参考文献,并联系领域专家。
- 纳入13篇关于钙/维生素D和19篇关于单用维生素D对比安慰剂/对照的SR/MA。
- 使用AMSTAR-2进行质量评估,通过矩阵和亚组分析比较结果并探究不一致原因。
主要发现
- 仅2/10篇钙/维生素D的SR/MA为中等质量。
- 钙/维生素D在8/12篇SR/MA中降低髋部骨折风险(RR 0.61-0.84),在7/11篇中降低任何骨折风险(RR 0.74-0.95)。
- 仅评估社区居住人群的SR/MA或单用维生素D对比安慰剂/对照的SR/MA未观察到骨折风险降低。
- SR/MA间结果不一致源于纳入不同试验(检索期限和入选标准)及不同方法学(意向性治疗、符合方案或完整病例分析)。
关键数值与推荐
- 钙/维生素D降低髋部骨折风险:RR 0.61-0.84(8/12篇SR/MA)。
- 钙/维生素D降低任何骨折风险:RR 0.74-0.95(7/11篇SR/MA)。
- 仅2/10篇钙/维生素D的SR/MA为中等质量(AMSTAR-2评估)。
临床怎么用
- 临床决策时应考虑钙/维生素D可能降低骨折风险,尤其对机构化人群。
- 单用维生素D或仅社区居住人群的骨折预防证据不支持显著获益。
- 解读SR/MA时需注意纳入试验和方法学差异对结果的影响。
局限性
- 多数SR/MA质量不高,仅2/10篇钙/维生素D的SR/MA为中等质量。
- 结果可能受机构化人群 findings 驱动,社区居住人群证据有限。
- SR/MA间方法学差异(意向性治疗、符合方案、完整病例分析)导致结果不一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The growing number of systematic reviews/meta-analyses (SR/MAs) on vitamin D (± calcium) for fracture prevention has led to contradictory guidelines. OBJECTIVE: This umbrella review aims to assess the quality and explore the reasons for the discrepancy of SR/MAs of trials on vitamin D supplementation for fracture risk reduction in adults. METHODS: We searched 4 databases (2010-2020), Epistemonikos, and references of included SRs/MAs, and we contacted experts in the field. We used A MeaSurement Tool to Assess systematic Reviews 2 (AMSTAR-2) for quality assessment. We compared results and investigated reasons for discordance using matrices and subgroup analyses (PROSPERO registration: CRD42019129540). We included 13 SR/MAs on vitamin D and calcium (Ca/D) and 19 SR/MAs on vitamin D alone, compared to placebo/control. RESULTS: Only 2 from 10 SRs/MAs on Ca/D were of moderate quality. Ca/D reduced the risk of hip fractures in 8 of 12 SRs/MAs (relative risk [RR] 0.61-0.84), and any fractures in 7 of 11 SR/MAs (RR 0.74-0.95). No fracture risk reduction was noted in SRs/MAs exclusively evaluating community-dwelling individuals or in those on vitamin D alone compared to placebo/control. Discordance in results between SRs/MAs stems from inclusion of different trials, related to search periods and eligibility criteria, and varying methodology (using intention to treat, per-protocol, or complete case analysis from individual trials). CONCLUSION: Ca/D reduces the risk of hip and any fractures, possibly driven by findings from institutionalized individuals. Individual participant data meta-analyses of patients on Ca/D with sufficient follow-up periods, and subgroup analyses, would unravel determinants for a beneficial response to supplementation.
引用
- Chakhtoura M, Bacha DS, Gharios C, et al. Vitamin D Supplementation and Fractures in Adults: A Systematic Umbrella Review of Meta-Analyses of Controlled Trials. J Clin Endocrinol Metab. 2022. PMID: 34687206. doi:10.1210/clinem/dgab742
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。